PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to control dangerous bleeding disorder
Disease control OngoingThis study is testing whether adding a new drug called ianalumab to standard steroid treatment helps adults with primary immune thrombocytopenia (ITP) maintain safer platelet counts and reduce bleeding risk. The trial involves 226 participants who will receive either ianalumab or…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for patients with stubborn blood disorder
Disease control OngoingThis study is testing an experimental drug called ianalumab for adults with primary immune thrombocytopenia (ITP), a condition where the immune system attacks blood platelets, increasing the risk of bleeding. It is for people whose ITP hasn't been controlled well by at least two …
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Feb 23, 2026 14:54 UTC